MaaT Pharma Announces New Appointments to the Board and Executive Team
21 Junho 2023 - 1:00PM
Business Wire
- Appointments to the Board of Directors and Executive team, to
align with the Company’s long-term vision and goals:
- Karim Dabbagh as Chairman and Nadia Kamal as Director, both
independent.
- Pr. Gervais Tougas, acting Chief Medical Officer and Philippe
Moyen, Chief Operating Officer.
- Appointment of Guilhaume Debroas as Head of Investor
Relations.
- All resolutions presented during the annual general meeting
were adopted in line with the Board recommendations.
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a
clinical-stage biotechnology company and a leader in the
development of Microbiome Ecosystem TherapiesTM (MET) dedicated to
improving survival outcomes for patients with cancer, today
announced new appointments to its Board and Executive team.
Board of Directors
- Karim Dabbagh, PhD, is appointed as Chairman and independent
Director, succeeding Jean-Marie Lefèvre who will continue to serve
as a Board member. Based in the U.S., Karim Dabbagh, president and
CEO of Second Genome Inc., is renowned for his innovative work in
microbiome science. As former executive at Pfizer and Roche, he
brings extensive experience in pharmaceutical development.
- Nadia Kamal, PhD, Director of the Technology, Health, and
Innovation Divisions at Harmonie Mutuelle has been appointed as
independent director and Chair of the ESG committee. Nadia Kamal
has a wealth of experience in Corporate Social Responsibility and a
strong background in serving patients and fostering
innovation.
- All other Directors and Observers have been reelected to serve
for an additional one-year term. Further details can be found on
the Company’s website.
“I express gratitude to Jean-Marie Lefèvre for his remarkable
5-year tenure as Chairman, who was instrumental in achieving key
milestones and has been a true partner for me. As we embark on the
next phase of growth post-IPO, our governance evolves, therefore, I
warmly welcome Karim Dabbagh to the team and am eager to continue
building a successful microbiome company together,” said Hervé
Affagard, CEO and co-founder of MaaT Pharma. "Our expanding
Early Access program and ongoing trials address the growing
interest from the medical community and patients. The potential for
microbiome therapies as valid therapeutic options for patients is
demonstrated by the successful commercialization of recently
approved products in the U.S. for C. difficile infection and the
2023 ASCO spotlight.”
Jean-Marie Lefèvre, former chairman of MaaT Pharma, said
“It has been an honor to serve alongside Hervé and his dedicated
and passionate team. As I pass the baton to Karim Dabbagh, I carry
with me a deep sense of fulfillment for what we have accomplished
and look forward to continuing to serve on the Board. “
Karim Dabbagh, new Chairman of the Board, stated “I am
thrilled to join one of the companies at the forefront of the
global microbiome field. The groundbreaking advancements and
pioneering research undertaken by MaaT Pharma have truly set them
apart. I look forward to contributing to their continued success as
we strive to make a lasting impact on the future of microbiome
innovation for patients, while delivering value to our
shareholders.”
Appointments to the Executive team and key leaders
- Appointment of Professor Gervais Tougas as Acting Chief Medical
Officer (CMO): supported by Dr. Emilie Plantamura, Head of Clinical
Development, Prof. Tougas will lead medical strategies for MaaT
Pharma's registration pathway in onco-hematology and clinical phase
in Immuno-oncology. Prior to joining MaaT Pharma, Gervais was the
Head, Chief Medical Officer and Patient Safety at Novartis for
almost 20 years.
- Appointment of Philippe Moyen, as Chief Operating Officer
(COO): former Vice-President of technical and business operations
for PTC Therapeutics Inc., Philippe Moyen has more than 20 years’
experience in the pharmaceutical and biotech industry, including
proven operational excellence and business acumen in small
molecules and Biologics that will enable him to effectively
contribute to the Company’s future milestones.
- Guilhaume Debroas, PhD, joins the Company as Head of Investor
Relations. Guilhaume brings instrumental biotech insight and a
strong network to enhance communication with the investment
community.
With these changes the Company is confident in its ability to
accelerate growth, deliver innovative microbiome drugs to patients,
and create value for shareholders.
Annual General Meeting
All resolutions presented during the annual general meeting were
adopted in line with Board recommendations, including the
resolutions (14 to 19) relating to the compensation policy for
corporate officers in respect of the 2023 financial year as
described in the Company's Universal Registration Document and on
the website.
The Company also announces, as per approval of resolution 20 and
21, that the Board of Directors, during its meeting on June 20,
2023, decided to maintain the liquidity agreement signed with
Kepler Cheuvreux for the trading of the Company's shares on
Euronext Paris. Information regarding this agreement is available
in the Company's Universal Registration Document published by the
Company.
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022, an open-label, single arm Phase 3 clinical trial in
patients with acute GvHD, following the achievement of its proof of
concept in a Phase 2 trial. Its powerful discovery and analysis
platform, gutPrint®, enables the identification of novel disease
targets, evaluation of drug candidates, and identification of
biomarkers for microbiome-related conditions. The company’s
Microbiome Ecosystem Therapies are produced through a standardized
cGMP manufacturing and quality control process to safely deliver
the full diversity of the microbiome, in liquid and oral
formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice. MaaT Pharma is listed on Euronext
Paris (ticker: MAAT).
Forward-looking Statements
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230621763384/en/
MaaT Pharma – Investor Relations Guilhaume Debroas, Ph.D.
Head of Investor Relations +33 4 28 29 14 00 invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 14 06 45 92
media@maat-pharma.com Trophic Communications – Corporate
Communications Charlotte SPITZ or Stephanie MAY +49 171 351
2733 maat@trophic.eu
Maat Pharma (EU:MAAT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Maat Pharma (EU:MAAT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024